<DOC>
	<DOCNO>NCT00659295</DOCNO>
	<brief_summary>This study conduct Africa , Asia , Europe , Japan South America . The aim observational study evaluate incidence serious adverse reaction ( SARs ) use Levemir速 ( insulin detemir ) normal clinical practice condition . Study conduct globally 26 country . Some country participate study 3 month ( Austria , Brazil , Denmark , Germany , Israel , Lebanon , Slovenia , Russia , Turkey ) , others extend participation 6 ( Belgium/Luxembourg , Czech Republic , Greece , India , Italy , Netherlands , Saudi Arabia , South Africa , South Korea , Sweden , Tunisia , United Kingdom/Ireland ) 12 month ( Finland , France , Japan ) , respectively .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Levemir速 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Age accord approve label country physician discretion Type 1 2 diabetes Recently start treatment insulin detemir discretion investigator . Before initiation insulin detemir treat insulin Selection discretion physician Current treatment Levemir速 ( insulin detemir ) Previously enrol study Hypersensitivity Levemir速 ( insulin detemir )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>